Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2024-04-08 Capital/Financing Update
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Quarterly Update – Cxbladder Test Volumes Steady in Q4 24
Capital/Financing Update Classification · 85% confidence The document is an announcement dated 9 April 2024 from Pacific Edge regarding steady test volumes in Q4 2024 and some operational details about sales force efficiency and test volumes. It provides quarterly and annual test volume data but does not contain comprehensive financial statements or detailed financial analysis. The document is relatively short (3988 characters) and reads like a business update or operational performance announcement rather than a full financial report. It does not appear to be an earnings release since it lacks key financial highlights or earnings figures, nor is it a full interim or annual report. It is also not a regulatory filing or certification. The content aligns best with a Capital/Financing Update (CAP) or possibly an Interim/Quarterly Report (IR). However, since it lacks substantive financial data and is more operational in nature, it is best classified as a Capital/Financing Update (CAP) type of announcement about business performance metrics and operational updates for the quarter.
2024-04-08 English
Quarterly Update - Cxbladder Test Volumes Steady in Q4 24 12 pages 1.4MB
Interim / Quarterly Report Classification · 95% confidence The document is an investor update from Pacific Edge dated April 2024, focusing on quarterly test volumes, clinical study results, sales force efficiency, and Medicare coverage updates. It contains detailed operational and clinical progress information, including quarterly and annual test volume data (Q4 24 and FY 24), clinical study updates (STRATA study), and management commentary from the CEO. The document is about quarterly operational and clinical performance with substantive data and analysis, not just a brief announcement or a certification. It is not a full annual report (10-K) but rather a detailed quarterly or interim report with financial and operational metrics and outlook. Therefore, the best fit is an Interim / Quarterly Report (IR). Q4 2024
2024-04-08 English
SPH Notice – Salt Funds Management Limited
Major Shareholding Notification Classification · 100% confidence The document is a disclosure of movement in substantial shareholding, specifically reporting a change in the percentage of shares held by Salt Funds Management Limited in Pacific Edge Limited. It includes details of transactions, dates, share quantities, and percentages held before and after the event. The document references the Financial Markets Conduct Act 2013 and is addressed to NZX Limited and the company. It is a notification of a major shareholding change, not a financial report, earnings release, or management discussion. The content fits the definition of a Major Shareholding Notification (MRQ). The document length is 3038 characters, which is consistent with a detailed notification rather than a full report or announcement of a report publication.
2024-03-15 English
Pacific Edge Directors Give Notice of Retirement
Board/Management Information Classification · 95% confidence The document is a company announcement dated 14 March 2024 regarding the retirement of two directors from the Board of Pacific Edge. It discusses governance changes, specifically the retirement of the Chair and a Non-Executive Director, and the process to appoint new directors. There is no financial data, earnings information, or detailed report content. The focus is on board membership changes and governance structure. This fits the category of Board/Management Information (MANG). The document length is 4678 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2024-03-13 English
Pacific Edge Directors Give Notice of Retirement 2 pages 112.2KB
Board/Management Information Classification · 95% confidence The document is a company announcement dated 14 March 2024 regarding the retirement of two directors from the Board of Pacific Edge. It discusses governance changes, intentions of the directors to retire or not seek re-election, and the process to appoint new directors. There is no financial data, no mention of a report being attached or published, and no regulatory filing or certification. The content is focused on changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 4678 characters, which is sufficient for a detailed announcement but does not contain financial statements or report data. Therefore, the correct classification is MANG with high confidence.
2024-03-13 English
Cxbladder Test Volumes Correction
Regulatory Filings Classification · 95% confidence The document is a short announcement correcting previously released test volume data for a specific quarter (Q3 24) and refers to a corrected press release and investor update being attached. It is brief (2174 characters) and does not contain detailed financial statements or substantive financial data. It primarily serves as a correction notice and update to prior information rather than a full financial or operational report. There is no indication of it being a full quarterly or annual report, earnings release, or other detailed filing. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and corrections that do not fit other specific categories.
2024-01-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.